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C isplatin is an antineoplastic drug for cancer treatment
in children and adults. The side effects of cisplatin
ototoxicity are significant: irreversible bilateral hearing
damage to high frequencies (4 kHz - 8 kHz). Reports
recognize some drugs that are associated with cisplatin to
obtain an otoprotector effect. The ototoxicity mechanisms
of cisplatin are related to injury of hair cell oxidation
mechanism, especially of outer hair cells. Aim: Using
otoacoustic emissions distortion products (DPOEA) and
scanning electron microscopy we intended to verify the
action of amifostine, a radioprotective drug that has well
known antioxidant characteristics and otoprotector effects
to cisplatin injury. Study design: Experimental. Material
and Method: We used an experimental guinea pig model.
The study was performed as follows: group 1: 6 animals,
12 ears, cisplatin 8.0 mg/Kg/day (IP), 3 days. Group 2: 6
animals, 12 ears, amifostine 100 mg/Kg/day (IP) and after
90 minutes, cisplatin 8.0 mg/Kg/day (IP), 3 days and group
3: 3 animals, 6 ears, amifostine 100 mg/Kg/day (IP), 3 days.
Results: DPOEA were present before and after treatment in
groups 2 and 3. The normal cilium architecture of outer
hair cells was supported in all cochlear turns in groups 2
and 3. We concluded that amifostine has a potential
otoprotector effect against cisplatin ototoxicity and could
be used in clinical trials.
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INTRODUCTION
The improvement in survival of patients with cancer
by using more effective antineoplastic drugs, such as cisplatin,
has favored the increase in incidence of side effects,
especially in the central nervous system, kidneys and hearing
system.1
Thus, different substances have been studied to try
to protect subjects from these effects, without reducing
antitumor activity of cisplatin.
Cisplatin causes bilateral symmetrical sensorineural loss
in frequencies of 4 to 8kHz, with association of tinnitus 2.
The incidence of ototoxicity is increased as the
accumulated dose of cisplatin is over 200mg/m2 of body
surface. As a result of high frequency audiometry studies,
the incidence of hearing loss has increased and reached up
to 70% for frequencies up to 16kHz 3.
McAlpine and Johnstone, 1990, in an experimental
study in guinea pigs observed damage to outer hair cells on
the basal turn of the cochlea, without damage to stria
vascularis 4.
Studies conducted in the 90’s had shown that
cisplatin inhibited the activity of adenylcyclase in stria
vascularis, inhibited DNA and RNA, protein synthesis and
increased levels of oxygen free radicals, which are toxic to
the cell.5
Ravi, 1995, showed that the cochlea might suffer
affections to its anti-oxidative capacity, with reduction of
cochlear glutation levels, reduction of glutation oxidase and
increase in activity of catalase and dismutase superoxide
enzymes.6
Different otoprotective drugs have been tested, and
most of them act as cell free anti-radical, among which
we can include amifostine (WR 2721, acid S - 2[3-
aminopropylamine] ethylphosphorothiol), developed by
Walter Red Army Institute, in the 50’s, to protect the toxic
effects of radiotherapy, without affecting the antitumoral
potential.7,8
Yuhas and Culo, 1980, were the first ones to show
that amifostine promoted a reduction in nephrotoxicity
induced by cisplatin, without affecting antitumor activity,
which was later confirmed by the studies conducted by
Glover et al., 1986 and 1987.7,9,10
Mollman et al., 1988, showed slight reduction in
ototoxicity of cisplatin in patients previously treated with
amifostine 11. Rubin et al., 1995, showed that there was no
ototoxicity in speech frequencies in any of the patients
treated with amifostine and cisplatin 12.
Amifostine is converted into an active sulphidic
compound,  named WR1065 ,  which ac t s  as  a
cytoprotector, chelating free radicals. There is selective
protection of amifostine to normal tissue cells, owing
to high concentration of this compound in tumor cells.
This fact is explained by reduction of alkaline
phosphatase activity in tumor cells, low tumor
vascularization and tumor anaerobe metabolism that
causes a with very low pH medium, which does not
allow intracellular entry of WR1065 because it requires
a ph between 6.6 and 8.2.7,8
In the 80’s, amifostine was approved by FDA to be
used in patients that received cisplatin to prevent cisplatin
nephrotoxicity 13. However, its use is not recommended in
cases of potentially curable tumors because the influence of
cisplatin in the efficacy of chemotherapy is not exactly known
yet 12,14.
We did not find any experimental study in the
literature that had confirmed outer hair cells’ protection by
amifostine to the toxic effects of cisplatin.
Two experimental studies in hamsters using surface
electron microscopy and brainstem evoked potential have
tested the otoprotection potential of amifostine and other
drugs to the effects of cisplatin. They showed that sodium
thiosulfate and diethyldithiocarbamate are more effective
as otoprotectors than amifostine and fosfomycin 15, 16.
We decided to study the otoprotective effects of
amifostine to damage to outer hair cells caused by cisplatin,
using functional measures through otoacoustic emission
distortion product and anatomical assessment of damage
caused to outer hair cells by electron scanning microscopy.
MATERIAL AND METHODS
Selection of Experimental Animals
The experimental animal selected was albino
guinea pigs since they are easy to handle and the cochlea
is easy to dissect, plus it is easy to infuse anesthetic
drugs and experimental drugs through intraperitoneal
access and they are more sensible to the effects of
cisplatin. The required dose is 8.0 mg/Kg/day for three
consecutive days, which leads to significant cochlear
affections.
Guinea pigs allow appropriate maintenance and
compliance with the guidelines of care and use of
laboratory animals of Institute of Laboratory Animal
Resources, Commission on Life Sciences, National
Research Council, National Academy Press, Washington,
DC. (1996).
Animals were selected at the Central Animal
Laboratory, University of Sao Paulo - Campus of Ribeirão
Preto, by studying Preyer’ reflex. We chose animals
weighting on average 400 and 600 grams, because they
were animals resistant to systemic side effects of cisplatin,
with lack of appetite, weight loss, dehydration and
diarrhea.17,18
After 24-hour hearing rest, animals were
reassessed and we conducted manual otoscopy.
Animals that presented signals of external or acute otitis
media, difficult to remove cerumen, inflammatory
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affections of external auditory canal, or even very
narrow canal to appropriately accommodate the probe
of the otoacoustic emissions, were excluded from the
study and those that presented easy to remove cerumen
were maintained.
Guinea pigs were submitted to hearing screening by
DPOAE in sound-proof booth and under anesthesia with
Ketamine (65 mg/Kg) and Xylazin (6.5 mg/Kg). The ones
that presented DPOAE in at least one of the ears were
selected for the experiment.
Animals were maintained in the Animal Laboratory of
the Experimental Surgery, Department of Surgery, Medical
School, Ribeirão Preto-USP.
Given that it was an experiment using systemic drugs,
for each tested animal we considered two cochleae and
animals that presented OAE in one ear were also used.
Drugs Used, Doses and Administration Route
1. Cisplatin (10 mg/ml) - 0.75; 1.5 and 8.0 mg/Kg/day
intraperitoneal access;
2. Xylazin (2g/100ml) - 6.5mg/Kg intraperitoneal access;
3. Ketamine Chlorhydrate (50 mg/ml) - 65mg/Kg -
intraperitoneal access;
4. Amifostine 100 mg/ Kg/ day - intraperitoneal access.
For controlled application of tested drugs, we used
1cc disposable syringes for each animal. For intraperitoneal
application, we used disposable BD syringes size 21G1 (25
X 8 - 0.8 x 25 millimeters).
Studied Groups
Group 1: 06 animals - 12 ears - cisplatin dose of 8.0 mg/
Kg/day, intraperitoneal access, for three days.
Group 2: 06 animals - 12 ears - Amifostine dose of 100 mg/
Kg/day, intraperitoneal access and 90 minutes
after, cisplatin 8.0 mg/Kg/day, intraperitoneal
access for three days.
Group 3: 03 animals - 06 ears - Amifostine dose of 100 mg/
Kg/day, intraperitoneal access for three days.
Auditory Functional Assessment
Distortion product otoacoustic emissions
Equipment: ILO 92 CAE System Otodynamics
LTD
Guinea pigs were anesthetized with Ketamine
Chlorhydrate and Xylazin before undergoing the tests. Before
OAE, they were submitted to manual otoscopy to assess
the external auditory canal and tympanic membrane, and
those with signals of otitis or difficult to remove cerumen
were excluded.
DPOAE was conducted before treatment and some
minutes before the animals were sacrificed, following the
frequency 2F1 - F2 with the ratio F1:F2 = 1.22, resolution of
two points per octave.
We considered OAE as of the frequency of 1.5 kHz,
because the dimensions of the external auditory canal of
guinea pigs result in difficulty to detect OAE below this
frequency, and the responses coincide with responses to
noise.
Thus, we analyzed the frequency of 2kHz, we
provided one pure tone above and another one below
it, so as the relation between them was 1.22,
automatically reaching the frequency response resulting
from the relat ion 2F1-F2 (below the assessed
frequency) and 2F2-F1 (above the resulting frequency).
We should also bear in mind that intensities F2 and F1
can be either similar or different. In the present study,
we used intensities that were similar to 70dB SPL. The
intensity of the triggering stimuli may vary from 0 to
70 dB SPL and it can be measured in the range 500 to
8000Hz.19
Resulting otoacoustic emissions are normally about
55 dB SPL less loud than the triggering stimulus. With 70 dB
SPL, the generated DPOAE would range approximately from
10 to 15 dB SPL 20.
Thus, we detected the DP gram, or audiocochleogram,
in which the stimulus is a sound and a response that is also
a sound and that provides information about the functions
of cochlear outer hair cells responsible for the analyzed
frequencies.21
In this study, what we considered as the most
important were OAE in high frequencies, which qualitatively
assess the functional status of outer hair cells in the basal
turn of the cochlea. We considered presence or absence of
DPOAE.
Anatomical Assessment
Scanning Electron Microscopy (SEM)
Equipment: Electron Microscope JEOL
SCANNING MICROSCOPE - JSM 5200
Guinea pigs were sacrificed in the scheduled time
after administration of drugs by intraperitoneal access and
anesthesia with ether, and they were decapitated and the
cochleae were removed with the bulla.
To carry out microscopic dissection of cochleae, we
performed perfusion with fixation solution of glutaraldehyde
at 3% at 4o Celsius and maintained them in the solution for
24 hours for fixation. The following steps were carried out
at the Laboratory of Electron Microscopy, Department of
Morphology, FMRP-USP:
Through the round window, we injected the
fixation solution of glutaraldehyde at 3% in buffer
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phosphate 0.1 M, pH = 7.4, for 4 hours at 4o Celsius,
rinsed three times for 5 minutes with the same buffer.
After dissecting the cochlea, it was fixed with osmium
tetroxide at 1% for 2 hours at 4o Celsius and submitted
to dehydration at room temperature in a growing battery
of ethanol (50%, 70%, 90% and 95% - once for 10
minutes in each concentration) and absolute ethanol
three times for 15 minutes. When the dehydration was
over, we followed it by drying by the critical point
method of CO
2
, in which the material was deprived from
water. After being fixed in the appropriate specimen
holder, the material was recovered in a vacuum chamber
with gold vapors and examined under scanning electron
microscopy.22-25
The results obtained by SEM, after being
photographed, were analyzed through cochleograms.
We used number counting of outer hair cells in the
cochlear turn, in a determined photographic field, and
we counted ten cells, present or absent, as shown below
in Figure 1.
Data were statistically analyzed using the statistical
software Statistical Package for Social Sciences - (S.P.S.S.).
We considered the comparison of results and
statistically treated only data referring to basal turn, which
is the most interesting aspect from the cisplatin damage
perspective. However, we showed absolute values,
plotted in the graph, with data referring to other cochlear
turns.
RESULTS
As to anatomical assessment of group 1, treated
with isolated cisplatin (8.0 mg/Kg/day for three
consecutive days) there was damage and absence of
hairs in the rows of outer hair cells at the level of the
basal turn, followed by turns 2 and 3. The most evident
affections were seen in the basal turn, but we also
observed c i l ia ry d is tor t ion wi th “v” pat tern
disarrangement (or “w” pattern), with folded hairs or
partial absence of one of the arms of the “v” pattern, as
in Figure 2. At the level of the inner hair cells, we also
observed affections to the hairs, with hairs present but
disarranged.
In Figure 3, we can observe the comparison by stria
in cochleae of groups 1, 2 and 3.
In the group previously treated with amifostine, we
observed maintenance of normal architecture of outer hair
cells, under scanning electron microscopy and distortion
product otoacoustic emissions, which were present in all
tested cochleae.
V V V V V V V V V V V V V V IHC.
V V V V V V V V V V V V V V OHC. 1st ROW
V V V V V V V V V V V V V V OHC. 2nd ROW
V V V V V V V V V V V V V V OHC. 3rd ROW
Figure 1. Schematic representation of cochleogram using counting of hair cells by turn, as follows:
V = normal hair cell
V = damaged hair cell
Figure 2. SEM, 1,500X magnification, cochlea of guinea pig in group
1.
Figure 3. Mean number of outer hair cells present in the cochlear
turns - basal, E2 and E3 found in groups 1, 2 and 3.
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As to statistical analysis of presented data, to com-
pare the variable number of outer hair cells in the
cochlear basal turn in groups 1, 2 and 3, we used the
non-parametric test by Kruskal-Wallis. We decided in
Figure 4. SEM, 1,000X magnification, cochlea of guinea pig in group
2.
Figure 5. Distortion product otoacoustic emissions in guinea pigs
treated with amifostine and cisplatin (group 2) (A) and in guinea pigs
treated with cisplatin (group 1) (B).
favor of a non-parametric methodology because data do
not follow the normal course with this variable
(Kolmogorov-Smirnoff test with p<0.001). The H0
hypothesis was:
H0: values of 3 groups were equivalent
X
H1: there is at least one pair of groups that differed
significantly.
If H0 was rejected, we would use Dunn post-hoc test
to check which were the detected differences.
We adopted pd0.05 as level of significance. The result
of the test was p<0.001, showing that there was significant
difference between the groups. Based on Dunn’s test, we
detected that the number of outer hair cells in Group 1
(CISPLATIN 8.0 mg/ Kg/day) was smaller than in Group 2
(amifostine 100 mg/Kg/day and CISPLATIN 8.0 mg/Kg/day),
which in turn was equal to the number in group 3 (amifostine
100 mg/Kg/day).
As to variable DPOAE, we considered the comparison
of presence and absence percentages. In group 1, we
reached 100% absences, with group of 12, and in groups 2
and 3, we reached 100% of presence with groups of 12
and 6. Based on such values shown by Fisher exact test, we
reached p<0.001 and groups 2 and 3 were equivalent and
significantly different from group 1.
DISCUSSION
Amifostine has shown low toxicity and good results
concerning ototoxic effects of radiotherapy as reported by
Foster Nora and Siden, 1997.13
Concerning otoprotection against antineoplastic
agents, especially cisplatin, Church et al. (1995), found an
electrophysiological study of encephalic evoked potential
in hamsters, protection by sodium thiosulfate and
diethyldimethylthiocarbamate, and they did not observe
effective protection against amifostine and fosfomycin 15.
Kaltenbach et al. (1997) analyzed the same drugs,
now associated with anatomical assessment by scanning
electron microscopy and brainstem evoked potential. They
found 91% maintenance of outer hair cells with sodium
thiosulfate, 68% with diethyldimethylcarbamate, 52% with
fosfomycin and 45% with amifostine .16
In spite of these experimental data in animals, studies
in humans with cisplatin for the treatment of different
neoplasms have shown a tendency to nephroprotection,
neuroprotection, otoprotection and myeloprotection from
toxic effects of cisplatin. Foster Nora and Siden, 1997,
reported that these studies comprised few subjects with
different types of tumors and antineoplastic agent
interactions, in addition to receiving different dosages of
cisplatin. 13
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Some cancer treatment centers have included in their
Guidelines the use of amifostine to prevent some toxic effects
of cisplatin, in specific and dose-dependent situations,
especially after authorization and standardization of its use
as of 1980 by FDA, as provided by the studies by Vincent et
al. (2003).26
We could observe that, in Albine guinea pigs treated
with cisplatin 90 minutes after administration of amifostine,
assessed functionally through distortion product otoacoustic
emissions and scanning electron microscopy, there was
functional and structural significant protection to acute
ototoxic effects of cisplatin, different from what was reported
by Kaltenbach et al. (1997), in hamsters, showing evidence
of the otoprotection potential of amifostine in acute treatment
with cisplatin, with doses known to be ototoxic. Such findings
may justify their indication of use, as performed in different
cancer centers, following the guidelines proposed by FDA
(1980).16
However, its use is not recommendable in cases of
potentially curable tumors because we do not know the
exact influence of cisplatin in the efficacy of
chemotherapy.12,14
CONCLUSION
Amifostine shows evident signals of otoprotection
from ototoxic effects produced by cisplatin in albino guinea
pigs.
However, its use is not recommendable in cases of
potentially curable tumors because we do not know what is
the exact influence of cisplatin in the efficacy of
chemotherapy.12,14
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